Abstract:Rationale: Gut microbiota plays a crucial role in cancer development and treatment. Studies show that although the gut microbiota is able to promote tumor growth, its presence also improves the efficacy of cancer treatment such as immunotherapy. To date, understanding of the potential impact of the gut microbiota on other treatment modalities such as cancer nanomedicine is still limited. In this study, we aimed to establish the relationship between gut microbiota and cancer nanomedicine, which can potentially open a new path in cancer treatment that combines gut microbiota modulation along with nanotherapeutics. Methods: Mice bearing 4T1 triple-negative breast cancer cells were subjected to gut microbiota modulation by antibiotics (ABX) treatment in the drinking water. Mice given normal water was used for control. The effects of ABX treatment towards gut bacteria was studied by RT-qPCR and 16S next generation sequencing of fecal samples. The mice were then subjected to liposomal doxorubicin (LipoDox) treatment and the amount of nanotherapeutics that accumulated in the tumors was quantified. For therapeutic efficacy, the mice were subjected to ABX treatment and given three injections of LipoDox or saline, while the tumor growth was monitored throughout. Results: Analysis of fecal bacterial content showed that ABX treatment resulted in depletion of gut microbiota. Quantification of LipoDox content revealed significantly increased accumulation in ABX tumor compared to control. Compared to LipoDox treatment alone, we found that combined gut microbiota depletion and LipoDox treatment resulted in augmented long-term anti-tumor efficacy and significantly improved median survival compared to LipoDox only (control vs ABX = 58.5 vs 74 days, p = 0.0002, n = 10 for both groups), with two mice surviving until the end of the experimental end point without experiencing relapse. We also identified the increase in vascular permeability of ABX-treated tumors correlated to for improved therapeutic efficacy and outcome. Conclusion: We showed that gut microbiota depletion led to enhanced tumor vascular permeability, which allowed a larger amount of LipoDox nanoparticles to accumulate in the tumor, leading to better long-term effects. Our results suggest that gut microbiota modulation may be exploited in combination with available nanomedicine-based therapeutics to improve cancer diagnosis, therapeutic efficacy and outcome.

Synergistic Target of Intratumoral Microbiome and Tumor by Metronidazole-Fluorouridine Nanoparticles

Abundance and Metabolism Disruptions of Intratumoral Microbiota by Chemical and Physical Actions Unfreeze Tumor Treatment Resistance

Clearing intratumoral bacteria to augment tumor-therapeutic response by engineering antimicrobial dendritic mesoporous silica nanomedicine

Depletion of gut microbiota improves the therapeutic efficacy of cancer nanomedicine

Nanoparticles Conjugated with Bacteria Targeting Tumors for Precision Imaging and Therapy.

Bacteria-based nanodrug for anticancer therapy

The application of bacteria-nanomaterial hybrids in antitumor therapy

Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics

Antibacterial Fusobacterium Nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐colonized Bacteria And Enhance Immunotherapy Against Colorectal Cancer

An intratumor bacteria-targeted DNA nanocarrier for multifaceted tumor microenvironment intervention

Microbiotic Nanomedicine for Tumor-Specific Chemotherapy-Synergized Innate/adaptive Antitumor Immunity

Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses

Systemic Administration with Bacteria-Inspired Nanosystems for Targeted Oncolytic Therapy and Antitumor Immunomodulation

An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria

Synergistic Brilliance: Engineered Bacteria and Nanomedicine Unite in Cancer Therapy

Improved Tumor Infiltration and Immunomodulation for Tumor Therapy: A Pathway Based on Tetrahedral Framework Nucleic Acids Coupled Bacterial Nanocells

Nanomedicine Hitchhiking on Bacteria for Treating Tumors

Bacteria-based Nanosystems for Enhanced Antitumor Therapy

Progress of Tumor-Resident Intracellular Bacteria for Cancer Therapy

Fusobacterium Nucleatum-Mimicking Nanovehicles to Overcome Chemoresistance for Breast Cancer Treatment by Eliminating Tumor-Colonizing Bacteria

Combination gut microbiota modulation and chemotherapy for orthotopic colorectal cancer therapy